Inhibition Mechanism of Antimalarial Drugs Targeting the Cytochrome bc1Complex

Luise Jacobsen, Peter Husen, Ilia A. Solov'Yov*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

43 Downloads (Pure)


Plasmodium falciparum (P. falciparum) is the main parasite known to cause malaria in humans. The antimalarial drug atovaquone is known to inhibit the Qo-site of the cytochrome bc1 complex of P. falciparum, which ultimately blocks ATP synthesis, leading to cell death. Through the years, mutations of the P. falciparum cytochrome bc1 complex, causing resistance to atovaquone, have emerged. The present investigation applies molecular dynamics (MD) simulations to study how the specific mutations Y279S and L282V, known to cause atovaquone resistance in malarial parasites, affect the inhibition mechanism of two known inhibitors. Binding free energy estimates were obtained through free energy perturbation calculations but were unable to confidently resolve the effects of mutations due to the great complexity of the binding environment. Meanwhile, basic mechanistic considerations from the MD simulations provide a detailed characterization of inhibitor binding modes and indicate that the Y279S mutation weakens the natural binding of the inhibitors, while no conclusive effect of the L282V mutation could be observed.

Original languageEnglish
JournalJournal of Chemical Information and Modeling
Issue number3
Pages (from-to)1334–1345
Publication statusPublished - 2021


Dive into the research topics of 'Inhibition Mechanism of Antimalarial Drugs Targeting the Cytochrome bc1Complex'. Together they form a unique fingerprint.

Cite this